Val S. Goodfellow, PhD, received his PhD in organic chemistry from the University of Michigan, and completed post-doctoral training in medicinal chemistry at the University of Wisconsin, Madison. Dr. Goodfellow has served in science leadership positions at BioFocus, Neurocrine Biosciences and Cortech. He began his career at Bristol Myers Squibb and is inventor on numerous patents in the area of anti-virals, inflammation, obesity and CNS diseases. He is inventor of compounds that have advanced to clinical trials in the area of inflammation and is a co-inventor of a drug now marketed for HBV infections. Califia Bio was founded for the purpose of bringing treatments for HIV Associated  Neurocognitive Disorders (HAND)  and other underserved neurodegenerative diseases to the clinic. Califia Bio is collaborating with the University of Rochester to develop treatments for HAND and Parkinson’s disease, as well as with researchers at Johns Hopkins University to develop DLK inhibitors as treatments for glaucoma.